Tissue origin : Cortico-cancellous heterologous bone mix
Tissue collagen : Preserved
Physical form : Slightly radiopaque granules
Composition : 100% granulated mix
Granulometry : 250-1000 µm 1000-2000 µm
Re-entry time : 4/5 months, depending on grafting site characteristics
Packaging : Vial: 0.25 g, 0.5 g, 1.0 g, 2.0 g
Product codes : 250-1000 µm M1052FS | 1 Vial | 0.25 g | Porcine M1052FE | 1 Vial | 0.25 g | Equine M1005FS | 1 Vial | 0.5 g | Porcine M1005FE | 1 Vial | 0.5 g | Equine M1010FS | 1 Vial | 1.0 g | Porcine M1010FE | 1 Vial | 1.0 g | Equine M1020FS | 1 Vial | 2.0 g | Porcine M1020FE | 1 Vial | 2.0 g | Equine 1000-2000 µm M0210FS | 1 Vial | 1.0 g | Porcine M0220FS | 1 Vial | 2.0 g | Porcine
GMDN code : 46425
A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures(1) (matrix and porous form) and presents highly osteoconductive properties(2,3). It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab. Gen-Os® is gradually resorbable and provides support in bone neoformation helping to preserve the original graft shape and volume(4). Moreover, thanks to its collagen content, the product facilitates blood clotting and the subsequent invasion of repairing and regenerative cells, favouring restitutio ad integrum of missing bone. Gen-Os® has proven to have marked hydrophilia(5), and it is ideal to mix with GFs(6).
Gen-Os® must always be hydrated and thoroughly mixed with either a few drops of sterile physiological solution (or patient's blood) to activate its collagen matrix and to enhance its adhesivity or with TSV Gel to increase graft stability in not self-contained defects. If necessary, it can as well be mixed with the drug selected for surgery.
Gen-Os®, a cortico-cancellous bone mix, has been the first product developed with the Tecnoss® innovative biotechnology and, due to its universal use, still is today the most demanded from the market. Gen-Os® has been successfully used and documented for alveolar ridge preservation(7) in combination with Evolution membranes: the application of this biomaterial limits the alveolar ridge width reduction that would naturally occur with spontaneous healing, preserving thus the alveolar ridge volume and allowing a correct second stage implant placement(8). Gen-Os® has been used for lateral access maxillary sinus lift(3) and dehiscence regeneration(9), always in association with Evolution membranes. Gen-Os® has been documented in periodontal regeneration of deep infrabony defects(10). Due to its collagen content, once hydrated Gen-Os® becomes very sticky and hydrophilic(5): it combines therefore extremely well with blood and is very stable once applied into the grafting site. Its cortico-cancellous composition allows a progressive resorption of osteoclastic type, with in parallel a similar rate of new bone formation(2): these unique properties allow a very good graft volume preservation, a healthy and well vascularized new bony tissue and, ultimately, a successful implant rehabilitation. Gen-Os® is in fact able to boost vascularization: in vitro(11) assays proved an increase in the secretion of VEGF by periodontal ligament cells (PDL) in the presence of Gen-Os®, as well as an enhanced proliferation of endothelial cells.
1 FIGUEIREDO M, HENRIQUES J, MARTINS G, GUERRA F, JUDAS F, FIGUEIREDO H PHYSICOCHEMICAL CHARACTERIZATION OF BIOMATERIALS COMMONLY USED IN DENTISTRY AS BONE SUBSTITUTES - COMPARISON WITH HUMAN BONE J BIOMED MATER RES B APPL BIOMATER, 2010 FEB; 92(2):409-19
2 NANNMARK U, SENNERBY L THE BONE TISSUE RESPONSES TO PREHYDRATED AND COLLAGENATED CORTICO-CANCELLOUS PORCINE BONE GRAFTS: A STUDY IN RABBIT MAXILLARY DEFECTS CLIN IMPLANT DENT RELAT RES, 2008 DEC;10(4):264-70
3 CASSETTA M, PERROTTI V, CALASSO S, PIATTELLI A, SINJARI B, IEZZI G BONE FORMATION IN SINUS AUGMENTATION PROCEDURES USING AUTOLOGOUS BONE, PORCINE BONE, AND A 50 : 50 MIXTURE: A HUMAN CLINICAL AND HISTOLOGICAL EVALUATION AT 2 MONTHS CLIN ORAL IMPLANTS RES, 2015 OCT;26(10):1180-4
4 CARDAROPOLI D, CARDAROPOLI G PRESERVATION OF THE POSTEXTRACTION ALVEOLAR RIDGE: A CLINICAL AND HISTOLOGIC STUDY INT J PERIODONTICS RESTORATIVE DENT, 2008 OCT; 28(5):469-77
5FIGUEIREDO A, COIMBRA P, CABRITA A, GUERRA F, FIGUEIREDO M COMPARISON OF A XENOGENEIC AND AN ALLOPLASTIC MATERIAL USED IN DENTAL IMPLANTS IN TERMS OF PHYSICO-CHEMICAL CHARACTERISTICS AND IN VIVO INFLAMMATORY RESPONSE MATER SCI ENG C MATER BIOL APPL, 2013 AUG 1;33(6):3506-13
6 MIJIRITSKY E, FERRONI L, GARDIN C, BRESSAN E, ZANETTE G, PIATTELLI A, ZAVAN B PORCINE BONE SCAFFOLDS ADSORB GROWTH FACTORS SECRETED BY MSCS AND IMPROVE BONE TISSUE REPAIR MATERIALS, 2017 SEP 8;10(9)
7 CHECCHI V, FELICE P, ZUCCHELLI G, BARAUSSE C, PIATTELLI M, PISTILLI R, GRANDI G, ESPOSITO M WIDE DIAMETER IMMEDIATE POST-EXTRACTIVE IMPLANTS VS DELAYED PLACEMENT OF NORMAL-DIAMETER IMPLANTS IN PRESERVED SOCKETS IN THE MOLAR REGION: 1-YEAR POST-LOADING OUTCOME OF A RANDOMISED CONTROLLED TRIAL EUR J ORAL IMPLANTOL, 2017;10(3):263-278
8 FESTA VM, ADDABBO F, LAINO L, FEMIANO F, RULLO PORCINE-DERIVED XENOGRAFT COMBINED WITH A SOFT CORTICAL MEMBRANE VERSUS EXTRACTION ALONE FOR IMPLANT SITE DEVELOPMENT: A CLINICAL STUDY IN HUMANS CLIN IMPLANT DENT RELAT RES, 2013 OCT;15(5):707-13
9 CASSETTA M, RICCI L, IEZZI G, DELL'AQUILA D, PIATTELLI A, PERROTTI V RESONANCE FREQUENCY ANALYSIS OF IMPLANTS INSERTED WITH A SIMULTANEOUS GRAFTING PROCEDURE: A 5-YEAR FOLLOW-UP STUDY IN MAN INT J PERIODONTICS RESTORATIVE DENT, 2012 OCT;32(5):581-9
10 ESPOSITO M, GRUSOVIN MG, LAMBERT F, MATOS S, PIETRUSKA M, ROSSI R, SALHI L, BUTI J THE EFFECTIVENESS OF A RESORBABLE BONE SUBSTITUTE WITH A RESORBABLE MEMBRANE IN THE TREATMENT OF PERIODONTAL INFRABONY DEFECT - A MULTICENTER RANDOMISED CONTROLLED TRIA EUR J ORAL IMPLANTOL, 2015;8(3):233-244
11 ROMBOUTS C, JEANNEAU C, CAMILLERI J, LAURENT P, ABOUT I CHARACTERIZATION AND ANGIOGENIC POTENTIAL OF XENOGENEIC BONE GRAFTING MATERIALS: ROLE OF PERIODONTAL LIGAMENT CELLS DENT MATER J, 2016 DEC 1;35(6):900-907